HCW Biologics Inc

For the period ended Mar 31, 2024. Filed May 15, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2024 · Filed May 15, 2024

HCWB$1.02-1.9%Stored close · as of Nov 6, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Balance sheets

Condensed Balance Sheets

	December 31,	March 31,
	2023	2024
Unaudited
ASSETS
Current assets:
Cash and cash equivalents	$3,595,101	$4,084,076
Accounts receivable, net	1,535,757	903,884
Secured note receivable	—	250,000
Prepaid expenses	1,042,413	783,423
Other current assets	230,916	187,267
Total current assets	6,404,187	6,208,650
Investments	1,599,751	1,599,751
Property, plant and equipment, net	20,453,184	22,590,779
Other assets	56,538	28,476
Total assets	$28,513,660	$30,427,656
LIABILITIES AND STOCKHOLDERS’ EQUITY
Liabilities
Current liabilities:
Accounts payable	$6,167,223	$10,493,416
Accrued liabilities and other current liabilities	2,580,402	2,919,190
Total current liabilities	8,747,625	13,412,606
Debt, net	6,304,318	8,274,449
Total liabilities	15,051,943	21,687,055
Commitments and contingencies (Note 8)
Stockholders’ equity:
Common stock:
Common, $0.0001 par value; 250,000,000 shares authorized and 36,025,104 shares issued at December 31, 2023; 250,000,000 shares authorized and 37,823,394 shares issued at March 31, 2024	3,603	3,782
Additional paid-in capital	83,990,437	86,737,203
Accumulated deficit	(70,532,323)	(78,000,384)
Total stockholders’ equity	13,461,717	8,740,601
Total liabilities and stockholders’ equity	$28,513,660	$30,427,656

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.